A potential role of ruxolitinib in leukemia

Bibliography

• Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008;19(4):379-90
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341(14):1051-62
   PubMed Web of Science ®Google Scholar
• Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51(1):15-36
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM. Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy. Cancer 1995;76(12):2393-417
   PubMed Web of Science ®Google Scholar
• Reis LA Smith MA, Gurney JG, Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995, National Cancer Institute, Bethesda; 1999
   Google Scholar
• Soslow RA, Baergen RN, Warnke RA. B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology. Cancer 1999;85(12):2648-54
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, O'Brien S, Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 2006;107(2):480-2
   PubMed Web of Science ®Google Scholar
• Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood 2003;102(2):442-8
   PubMed Web of Science ®Google Scholar
• Ravandi F, Kantarjian H, Giles F, Cortes J. New agents in acute myeloid leukemia and other myeloid disorders. Cancer 2004;100(3):441-54
   PubMed Web of Science ®Google Scholar
• Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003;98(7):1337-54
   PubMed Web of Science ®Google Scholar
• Farag SS, Ruppert AS, Mrozek K, Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol 2005;23(3):482-93
   PubMed Web of Science ®Google Scholar
• Stone RM, Mayer RJ. Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematol Oncol Clin North Am 1993;7(1):47-64
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Davis RB, Schiffer CA, Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331(14):896-903
   PubMed Web of Science ®Google Scholar
• Bishop JF. The treatment of adult acute myeloid leukemia. Semin Oncol 1997;24(1):57-69
   PubMed Web of Science ®Google Scholar
• Laport GF, Larson RA. Treatment of adult acute lymphoblastic leukemia. Semin Oncol 1997;24(1):70-82
   PubMed Web of Science ®Google Scholar
• Hoelzer D. Treatment of acute lymphoblastic leukemia. Semin Hematol 1994;31(1):1-15
   PubMed Web of Science ®Google Scholar
• Preti A, Kantarjian HM. Management of adult acute lymphocytic leukemia: present issues and key challenges. J Clin Oncol 1994;12(6):1312-22
   PubMed Web of Science ®Google Scholar
• Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995;85(5):1151-68
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Gokbuget N. New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin Oncol 2000;27(5):540-59
   PubMed Web of Science ®Google Scholar
• Takeuchi J, Kyo T, Naito K, Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002;16(7):1259-66
   PubMed Web of Science ®Google Scholar
• Storring JM, Minden MD, Kao S, Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol 2009;146(1):76-85
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O'Brien S, Smith T, Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen. Br J Haematol 1994;88(1):94-100
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Walters RS, Keating MJ, Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia. Cancer 1989;64(1):16-22
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352(17):1779-90
   PubMed Web of Science ®Google Scholar
• Verstovsek S. Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program 2009;636-42
   PubMedGoogle Scholar
• James C, Ugo V, Le Couedic JP, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434(7037):1144-8
   PubMed Web of Science ®Google Scholar
• Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411(6835):355-65
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103(2):211-25
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;355(23):2452-66
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 2008;19(4):385-93
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228(1):273-87
   PubMed Web of Science ®Google Scholar
• Darnell J Jr. STATs and gene regulation. Science (Wash DC) 1997;277:1630-5
   PubMed Web of Science ®Google Scholar
• Rane SG, Reddy EP. JAKs, STATs and Src kinases in hematopoiesis. Oncogene 2002;21(21):3334-58
   PubMed Web of Science ®Google Scholar
• Darnell J Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (Wash DC) 1994;264:1415-21
   PubMed Web of Science ®Google Scholar
• Fu XY, Schindler C, Improta T, The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction. Proc Natl Acad Sci USA 1992;89(16):7840-3
   PubMed Web of Science ®Google Scholar
• Khan KD, Shuai K, Lindwall G, Jr, Bothwell AL. Induction of the Ly-6A/E gene by interferon alpha/beta and gamma requires a DNA element to which a tyrosine-phosphorylated 91-kDa protein binds. Proc Natl Acad Sci USA 1993;90(14):6806-10
   PubMed Web of Science ®Google Scholar
• Schindler C. STATs as activators of apoptosis. Trends Cell Biol 1998;8(3):97-8
   PubMed Web of Science ®Google Scholar
• Mui AL. The role of STATs in proliferation, differentiation, and apoptosis. Cell Mol Life Sci 1999;55(12):1547-58
   PubMed Web of Science ®Google Scholar
• Chin Y, Kitagawa M, Su WC, Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science (Wash DC) 1996;272:719-22
   PubMed Web of Science ®Google Scholar
• Mui AL, Wakao H, Kinoshita T, Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation. EMBO J 1996;15(10):2425-33
   PubMed Web of Science ®Google Scholar
• O'Farrell AM, Liu Y, Moore KW, Mui AL. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J 1998;17(4):1006-18
   PubMed Web of Science ®Google Scholar
• Chaturvedi P, Reddy MV, Reddy EP. Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation. Oncogene 1998;16(13):1749-58
   PubMed Web of Science ®Google Scholar
• Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008;112(6):2190-8
   PubMed Web of Science ®Google Scholar
• Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000;20(10):3387-95
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365(9464):1054-61
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7(4):387-97
   PubMed Web of Science ®Google Scholar
• Zhao R, Xing S, Li Z, Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280(24):22788-92
   PubMed Web of Science ®Google Scholar
• Collaborative study of karyotypes in childhood acute lymphoblastic leukemias. Groupe Francais de Cytogenetique Hematologique. Leukemia 1993;7(1):10-19
   PubMedGoogle Scholar
• Raimondi SC. Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood 1993;81(9):2237-51
   PubMed Web of Science ®Google Scholar
• Lacronique V, Boureux A, Valle VD, A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science (Wash DC) 1997;278:1309-12
   PubMed Web of Science ®Google Scholar
• Peeters P, Raynaud SD, Cools J, Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997;90(7):2535-40
   PubMed Web of Science ®Google Scholar
• Ikezoe T, Kojima S, Furihata M, High levels of p-JAK2 are associated with adverse clinical outcome and can be a molecular target in individuals with acute myelogenous leukemia. Int J Cancer. [Epub ahead of print]
   Google Scholar
• Ikezoe T, Yang J, Nishioka C, Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34(+)/CD38(-) cells and sensitizes them to antileukemia agents. Int J Cancer 2011;128(10):2317-25
   PubMed Web of Science ®Google Scholar
• Pradhan A, Lambert QT, Reuther GW. Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor. Proc Natl Acad Sci USA 2007;104(47):18502-7
   PubMed Web of Science ®Google Scholar
• Wang Y, Cai D, Brendel C, Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 2007;109(5):2147-55
   PubMed Web of Science ®Google Scholar
• Hariharan IK, Adams JM. Cory S. bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia. Oncogene Res 1988;3(4):387-99
   PubMedGoogle Scholar
• Jiang X, Lopez A, Holyoake T, Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci USA 1999;96(22):12804-9
   PubMed Web of Science ®Google Scholar
• Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998;92(10):3829-40
   PubMed Web of Science ®Google Scholar
• Cross NC, Daley GQ, Green AR, BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia 2008;22(11):1975-89
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363(12):1117-27
   PubMed Web of Science ®Google Scholar
• Hexner EO, Serdikoff C, Jan M, Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008;111(12):5663-71
   PubMed Web of Science ®Google Scholar
• Moliterno AR, Roboz GJ, Carroll M, An open-label study of CEP-701 in patients with JAK2 V617F-positive polycythemia vera and essential thrombocytosis. ASH Annual Meeting Abstracts. Blood 2008;112(11):99
   Google Scholar
• Geron I, Abrahamsson AE, Barroga CF, Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 2008;13(4):321-30
   PubMed Web of Science ®Google Scholar
• Wernig G, Kharas MG, Okabe R, Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13(4):311-20
   PubMed Web of Science ®Google Scholar
• Pardanani A, Gotlib JR, Jamieson C, Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29(7):789-96
   PubMed Web of Science ®Google Scholar
• Shi JG, Chen X, McGee RF, The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. [Epub ahead of print]
   Google Scholar
• Shilling AD, Nedza FM, Emm T, Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos Nov;38(11):2023-31
   PubMedGoogle Scholar
• Quintas-Cardama A, Vaddi K, Liu P, Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115(15):3109-17
   PubMed Web of Science ®Google Scholar
• Ravandi F, Verstovsek S, Estrov Z, Significant Activity of the JAK2 inhibitor, INCB018424 in patients with secondary, post-myeloproliferative disorder (MPD) acute myeloid leukemia (sAML): results of an exploratory phase II study. ASH Annual Meeting Abstracts. Blood 2009;114(22):261. abstract no. 631
   PubMed Web of Science ®Google Scholar
• Eghtedar A, Verstovsek S, Cortes JE, Phase II study of the JAK2 inhibitor, INCB018424, in patients with refractory leukemias including post-myeloproliferative disorder (MPD) acute myeloid leukemia (sAML). ASH Annual Meeting Abstracts. Blood 2010;116(21):225. abstract no. 509
   Web of Science ®Google Scholar
• Available from: http://www.clinicaltrials.gov
   Google Scholar